Perforating Folliculitis–Like Reaction Related to Sorafenib

Sorafenib, an oral multitargeted kinase inhibitor affecting tumor cell angiogenesis and proliferation, is approved for the treatment of advanced renal cell carcinoma, unresectable hepatocellular carcinoma, and differentiated thyroid carcinoma. However, approximately 70% to 80% of patients may experience cutaneous side effects with sorafenib, including hand-foot skin reaction (HSFR), rash and/or desquamation, alopecia, pruritus, xerosis, facial erythema, and subungual splinter hemorrhage.